{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:06:46Z","timestamp":1774649206750,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Iberoamericana de Micolog\u00eda"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.riam.2010.01.007","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T08:42:05Z","timestamp":1269506525000},"page":"49-56","source":"Crossref","is-referenced-by-count":17,"title":["Antif\u00fangicos disponibles para el tratamiento de las micosis ungueales"],"prefix":"10.1016","volume":"27","author":[{"given":"Alfonso Javier","family":"Carrillo-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Tur-Tur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Hern\u00e1ndez-Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia","family":"C\u00e1rdenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Giusiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.riam.2010.01.007_bib1","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/AAC.43.6.1520","article-title":"In vitro antifungal susceptibilities of Scopulariopsis isolates","volume":"43","author":"Aguilar","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib2","unstructured":"Armijo M, editor. Dermatosis por hongos. Madrid: Editorial M\u00e9dica Internacional SA; 1989."},{"key":"10.1016\/j.riam.2010.01.007_bib3","series-title":"Micosis que afectan piel y mucosas","first-page":"137","article-title":"Tratamiento farmacol\u00f3gico de las micosis","author":"Bada Ainsa","year":"1989"},{"key":"10.1016\/j.riam.2010.01.007_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2133.2001.00045.x","article-title":"Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis","volume":"145","author":"Baran","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/14656566.6.4.609","article-title":"Pharmacotherapy of onychomycosis","volume":"6","author":"Baran","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.riam.2010.01.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-3083.2004.00988.x","article-title":"Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy","volume":"19","author":"Baran","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.riam.2010.01.007_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/09546630701243418","article-title":"Review of antifungal therapy and the severity index for assessing onychomycosis: Part I","volume":"19","author":"Baran","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.riam.2010.01.007_bib8","first-page":"1260","article-title":"The management of onychomycosis","volume":"130","author":"Baran","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.riam.2010.01.007_bib9","first-page":"662","article-title":"AN-2690, a novel antifungal for the topical treatment of onychomycosis","volume":"8","author":"Barak","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.riam.2010.01.007_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/157488407779422311","article-title":"Clinical pharmacokinetics of systemically administered antimycotics","volume":"2","author":"Bellmann","year":"2007","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.riam.2010.01.007_bib11","first-page":"57","article-title":"The treatment of onychomycosis with miconazole tincture","volume":"62","author":"Bentley-Phillips","year":"1982","journal-title":"S Afr Med J"},{"key":"10.1016\/j.riam.2010.01.007_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1525-1470.2000.01761.x","article-title":"Onychomycosis in children: Treatment with bifonazole-urea","volume":"17","author":"Bonifaz","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib13","first-page":"107","article-title":"Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis","volume":"10","author":"Bonifaz","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib14","series-title":"Current topics in medical Mycology","first-page":"1","article-title":"Ultraestructural correlates of antimycotic treatment","author":"Borgers","year":"1989"},{"key":"10.1016\/j.riam.2010.01.007_bib15","first-page":"1368","article-title":"Effects of subinhibitory concentrations of ciclopirox in the adherence of Candida albicans to human bucal and vaginal cells","volume":"42","author":"Braga","year":"1992","journal-title":"Arzn Forch"},{"key":"10.1016\/j.riam.2010.01.007_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1100\/tsw.2004.134","article-title":"Evaluation of the drug treatment and persistence of onychomycosis","volume":"4","author":"Campbell","year":"2004","journal-title":"Scientific World Journal"},{"key":"10.1016\/j.riam.2010.01.007_bib17","first-page":"564","article-title":"Etiolog\u00eda de las dermatomicosis ungueales","volume":"43","author":"Carrillo-Mu\u00f1oz","year":"2004","journal-title":"Actualidad Dermatol\u00f3gica"},{"key":"10.1016\/j.riam.2010.01.007_bib18","first-page":"4","article-title":"Una nueva generaci\u00f3n de f\u00e1rmacos antif\u00fangicos","volume":"18","author":"Carrillo-Mu\u00f1oz","year":"2001","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2010.01.007_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1130-1406(05)70019-X","article-title":"Actividad antif\u00fangica de voriconazol frente a hongos dermatofitos y Scopulariopsis brevicaulis determinada por el m\u00e9todo de difusi\u00f3n en agar NeoSensitabs","volume":"22","author":"Carrillo-Mu\u00f1oz","year":"2005","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2010.01.007_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000072449","article-title":"In vitro activity of sertaconazole against dermatophyte moulds isolates with reduced fluconazole susceptibility","volume":"49","author":"Carrillo-Mu\u00f1oz","year":"2003","journal-title":"Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijantimicag.2008.01.023","article-title":"Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis","volume":"31","author":"Carrillo-Mu\u00f1oz","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2010.01.007_bib22","first-page":"130","article-title":"Mecanismos de acci\u00f3n de antif\u00fangicos en levaduras","volume":"19","author":"Carrillo-Mu\u00f1oz","year":"2006","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.riam.2010.01.007_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1586\/14787210.3.3.333","article-title":"Sertaconazole: Updated review of a topical antifungal agent","volume":"3","author":"Carrillo-Mu\u00f1oz","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.riam.2010.01.007_bib24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijantimicag.2007.04.004","article-title":"In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis","volume":"30","author":"Carrillo-Mu\u00f1oz","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.riam.2010.01.007_bib25","first-page":"181","article-title":"Nuevos antif\u00fangicos","volume":"12","author":"Carrillo-Mu\u00f1oz","year":"1999","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.riam.2010.01.007_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2174\/1568012043353766","article-title":"Current developments in antifungal agents: Present and future","volume":"3","author":"Carrillo-Mu\u00f1oz","year":"2004","journal-title":"Curr Med Chem Anti-Infect Agents"},{"key":"10.1016\/j.riam.2010.01.007_bib27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000007295","article-title":"Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole","volume":"46","author":"Carrillo-Mu\u00f1oz","year":"2000","journal-title":"Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib28","first-page":"235","article-title":"In vitro antifungal activity of sertaconazole and bifonazole against dermatophytes","volume":"5","author":"Carrillo-Mu\u00f1oz","year":"1995","journal-title":"J Mycol Med"},{"key":"10.1016\/j.riam.2010.01.007_bib29","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00042737-200109000-00021","article-title":"Terbinafine-induced hepatic dysfunction","volume":"13","author":"Chambers","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.riam.2010.01.007_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.amjmed.2007.03.021","article-title":"The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: A meta-analysis","volume":"120","author":"Chang","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.riam.2010.01.007_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5694\/j.1326-5377.2007.tb01313.x","article-title":"Antifungal agents","volume":"187","author":"Chen","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.riam.2010.01.007_bib32","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1128\/AAC.00162-06","article-title":"In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib33","first-page":"69","article-title":"Tratamiento actual de las dermatofitosis","volume":"19","author":"Del Palacio","year":"2002","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2010.01.007_bib34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2515\/therapie:2006041","article-title":"Use of topical antifungal agents","volume":"61","author":"Dupont","year":"2006","journal-title":"Therap"},{"key":"10.1016\/j.riam.2010.01.007_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00128071-200001010-00002","article-title":"Onychomycosis. Treatment, quality of life, and economic issues","volume":"1","author":"Elewski","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib36","first-page":"293","article-title":"In vitro antifungal susceptibility methods and clinical applications of antifungal resistance","volume":"38","author":"Espinel-Ingroff","year":"2000","journal-title":"J Mycol"},{"key":"10.1016\/j.riam.2010.01.007_bib37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2133.149.s65.1.x","article-title":"Drug synergies and the potential for combination therapy in onychomycosis","volume":"149","author":"Evans","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/000155557300304","article-title":"Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250mg terbinafine orally once per day for four weeks","volume":"73","author":"Faergemann","year":"1993","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.riam.2010.01.007_bib39","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1128\/AAC.45.9.2524-2528.2001","article-title":"In vitro of ten antifungal drugs against 508 strains of dermatophytes","volume":"45","author":"Fern\u00e1ndez-Torres","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2007.00109.x","article-title":"Toenail onychomycosis: Current and future treatment options","volume":"20","author":"Finch","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.riam.2010.01.007_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1439-0507.2004.01090.x","article-title":"New insights into the effect of amorolfine nail lacquer","volume":"48","author":"Flagothier","year":"2005","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/CMR.1.2.187","article-title":"Overview of medically important antifungal azole derivatives","volume":"1","author":"Fromtling","year":"1988","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.riam.2010.01.007_bib43","first-page":"319","article-title":"Onicomicosis causadas por hongos no dermatofitos en C\u00e1diz","volume":"18","author":"Garc\u00eda-Martos","year":"2000","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.riam.2010.01.007_bib44","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1128\/JCM.00818-06","article-title":"Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial","volume":"44","author":"Ghannoum","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.riam.2010.01.007_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1439-0507.2008.01540.x","article-title":"Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model","volume":"52","author":"Ghannoum","year":"2009","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2133.2007.08014.x","article-title":"Combination of surgical avulsion and topical therapy for single nail onychomycosis: A randomized controlled trial","volume":"157","author":"Grover","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib47","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1067\/mjd.2000.109069","article-title":"Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib48","first-page":"1","article-title":"Ciclopirox nail lacquer topical solution 8%","volume":"6","author":"Gupta","year":"2000","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.riam.2010.01.007_bib49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7547\/87507315-92-5-272","article-title":"Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis","volume":"92","author":"Gupta","year":"2002","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.riam.2010.01.007_bib50","first-page":"13","article-title":"Ciclopirox nail lacquer: A brush with onychomycosis","volume":"68","author":"Gupta","year":"2001","journal-title":"Cutis"},{"key":"10.1016\/j.riam.2010.01.007_bib51","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1067\/mjd.2000.109068","article-title":"Ciclopirox nail lacquer solution 8% in the 21st century","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib52","first-page":"16","article-title":"Onychomycosis: Management and treatment","volume":"74","author":"Gupta","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.riam.2010.01.007_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11046-008-9109-0","article-title":"Update in antifungal therapy of dermatophytosis","volume":"166","author":"Gupta","year":"2008","journal-title":"Mycopathol"},{"key":"10.1016\/j.riam.2010.01.007_bib54","first-page":"5","article-title":"Management of onychomycosis: Examining the role of monotherapy and dual, triple, or quadruple therapies","volume":"74","author":"Gupta","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.riam.2010.01.007_bib55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200405040-00003","article-title":"Optimal management of fungal infections of the skin, hair, and nails","volume":"5","author":"Gupta","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib56","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.2310\/7750.2006.00057","article-title":"Pharmacoeconomic assessment of ciclopirox topical solution, 8%, oral terbinafine, and oral itraconazole for onychomycosis","volume":"10","author":"Gupta","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.riam.2010.01.007_bib57","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7547\/87507315-90-10-502","article-title":"Ciclopirox nail lacquer and podiatric practice","volume":"90","author":"Gupta","year":"2000","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.riam.2010.01.007_bib58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0733-8635(03)00026-3","article-title":"How to improve cure rates for the management of onychomycosis","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.riam.2010.01.007_bib59","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0733-8635(03)00025-1","article-title":"The use of topical therapies to treat onychomycosis","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.riam.2010.01.007_bib60","first-page":"302","article-title":"The use of terbinafine in the treatment of onychomycosis in adults and special populations: A review of the evidence","volume":"4","author":"Gupta","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10227-003-0109-x","article-title":"Treatment of onychomycosis: Pros and cons of antifungal agents","volume":"8","author":"Gupta","year":"2004","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.riam.2010.01.007_bib62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2133.2001.145s60003.x","article-title":"The future of onychomycosis therapy may involve a combination of approaches","volume":"145","author":"Hay","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib63","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/0378-6323.37056","article-title":"An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis","volume":"73","author":"Jaiswal","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.riam.2010.01.007_bib64","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00019053-200119040-00007","article-title":"Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: An an\u00e1lisis of based on results from the L.I.ON. Study. Lamisil versus itraconazole in onychomycosis","volume":"19","author":"Jansen","year":"2001","journal-title":"Pharmacoecon"},{"key":"10.1016\/j.riam.2010.01.007_bib65","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1128\/AAC.43.5.1260","article-title":"In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mould pathogens","volume":"43","author":"Johnson","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib66","first-page":"1471","article-title":"How should managed care treat onychomycosis?","volume":"4","author":"Katz","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.riam.2010.01.007_bib67","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00019053-200119100-00002","article-title":"Which antifungal agent for onychomycosis? A pharmacoeconomic analysis","volume":"19","author":"Joish","year":"2001","journal-title":"Pharmacoecon"},{"key":"10.1016\/j.riam.2010.01.007_bib68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0255-0857.40522","article-title":"Onychomycosis: Epidemiology, diagnosis and management","volume":"26","author":"Kaur","year":"2008","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.riam.2010.01.007_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/10408449709078444","article-title":"Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment","volume":"27","author":"Knasm\u00fcller","year":"1997","journal-title":"Crit Rev Toxicol"},{"key":"10.1016\/j.riam.2010.01.007_bib70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1439-0507.1997.tb00227.x","article-title":"The hydroxypyridones: A class of antimycotics of its own","volume":"40","author":"Korting","year":"1997","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib71","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1128\/AAC.39.5.1206","article-title":"Results of german mulcicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium","volume":"39","author":"Korting","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-2133.149.s65.3.x","article-title":"Pharmacoeconomic issues in onychomycosis","volume":"149","author":"Lambert","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib73","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2133.2001.145s60021.x","article-title":"Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain","volume":"145","author":"Lecha","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1468-3083.2005.01284.x","article-title":"Taskforce on onychomycosis education. Treatment options--development of consensus guidelines","volume":"19","author":"Lecha","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.riam.2010.01.007_bib75","first-page":"35","article-title":"Experience in the treatment of skin mycoses with ciclopiroxolamine","volume":"17","author":"Lecha-Carralero","year":"1989","journal-title":"Med Cutanea Ibero Lat Am"},{"key":"10.1016\/j.riam.2010.01.007_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2008.01523.x","article-title":"Antifungal agents-clinical pharmacokinetics and drug interactions","volume":"51","author":"Lipp","year":"2008","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib77","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002512-200724040-00003","article-title":"Onychomycosis in the elderly: Drug treatment options","volume":"24","author":"Loo","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.riam.2010.01.007_bib78","first-page":"127","article-title":"Tratamiento actual de las oniconicosis","volume":"19","author":"Llambrich","year":"2002","journal-title":"Rev Iberoam Micol"},{"key":"10.1016\/j.riam.2010.01.007_bib79","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4103\/0378-6323.16619","article-title":"An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis","volume":"71","author":"Mishra","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.riam.2010.01.007_bib80","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1517\/17425240802497218","article-title":"Enhancing the nail permeability of topically applied drugs","volume":"5","author":"Murdan","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.riam.2010.01.007_bib81","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1253\/circj.71.1323","article-title":"Frequent premature ventricular contractions induced by itraconazole","volume":"71","author":"Okamoto","year":"2007","journal-title":"Circ J"},{"key":"10.1016\/j.riam.2010.01.007_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2133.149.s65.2.x","article-title":"Combination therapy for onychomycosis","volume":"149","author":"Olafsson","year":"2003","journal-title":"Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib83","first-page":"23","article-title":"Ciclopiroxolamine: Clinical and microbiological considerations. Preliminary data","volume":"5","author":"Oliveri","year":"1986","journal-title":"Chimioterapia"},{"key":"10.1016\/j.riam.2010.01.007_bib84","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1128\/JCM.39.1.385-388.2001","article-title":"Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method","volume":"39","author":"Perea","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.riam.2010.01.007_bib85","first-page":"1630","article-title":"In vitro skin penetration of griseofulvin in rat and human skin from an ointment dosage form","volume":"38","author":"Ritschel","year":"1988","journal-title":"Arzneim Fosch"},{"key":"10.1016\/j.riam.2010.01.007_bib86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1439-0507.1999.tb00026.x","article-title":"Activity of terbinafine against serious fungal pathogens","volume":"42","author":"Ryder","year":"1999","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib87","first-page":"2852","article-title":"Study on patient satisfaction with the treatment of mycosis on the extremities with terbinafine (SETTA)","volume":"96","author":"S\u00e1nchez-Schmidt","year":"2005","journal-title":"Act Dermosifiliogr"},{"key":"10.1016\/j.riam.2010.01.007_bib88","first-page":"1249","article-title":"A review of the new antifungals: Posaconazole, micafungin, and anidulafungin","volume":"6","author":"Scheinfeld","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.149.s65.5.x","article-title":"Onychomycosis in clinical practice: factors contributing to recurrence","volume":"149","author":"Scher","year":"2003","journal-title":"Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib90","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.0933-7407.2003.00932.x","article-title":"Action mechanisms of modern antifungal agents and resulting problems in the management of onychomycosis","volume":"46","author":"Seebacher","year":"2003","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib91","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1157\/13052331","article-title":"In vitro activity of voriconazole and three other antifungal agents against dermatophytes","volume":"21","author":"Serrano-Martino","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.riam.2010.01.007_bib92","first-page":"159","article-title":"Treatment of onychomycosis using 40% urea with 1% bifonazole","volume":"122","author":"Shemer","year":"1992","journal-title":"Harefuah"},{"key":"10.1016\/j.riam.2010.01.007_bib93","first-page":"17","article-title":"A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers","volume":"26","author":"Sidou","year":"2004","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.riam.2010.01.007_bib94","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.48.1.216-223.2004","article-title":"Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum","volume":"48","author":"Sobue","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib95","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00019053-200119030-00005","article-title":"Cost of treatment for onychomycosis. Data from a 9-month observational study","volume":"19","author":"Stier","year":"2001","journal-title":"Pharmacoecon"},{"key":"10.1016\/j.riam.2010.01.007_bib96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0536.1992.tb00285.x","article-title":"Contact allergy to tioconazole. Contact allergy to tioconazole","volume":"26","author":"Stubb","year":"1992","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.riam.2010.01.007_bib97","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00128071-200607040-00007","article-title":"Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation","volume":"7","author":"Susilo","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib98","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1439-0507.2004.00968.x","article-title":"Onychomycosis in Denmark: Prevalence of fungal nail infection in general practice","volume":"47","author":"Svejgaard","year":"2004","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib99","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/bmj.38007.711481.F7","article-title":"Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study","volume":"328","author":"\u2019t Jong","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.riam.2010.01.007_bib100","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/AAC.46.12.3797-3801.2002","article-title":"Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine","volume":"46","author":"Tatsumi","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.riam.2010.01.007_bib101","first-page":"1","article-title":"Ciclopiroxolamina. Un nuevo antif\u00fangico t\u00f3pico, uso terap\u00e9utico","volume":"25","author":"Torres","year":"1989","journal-title":"Drugs Today"},{"key":"10.1016\/j.riam.2010.01.007_bib102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/03639040701199225","article-title":"Delivery of itraconazole from extruded HPC films","volume":"33","author":"Trey","year":"2007","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.riam.2010.01.007_bib103","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7547\/87507315-93-5-373","article-title":"Satisfaction with onychomycosis treatment. Pulse versus continuous dosing","volume":"93","author":"Warshaw","year":"2003","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.riam.2010.01.007_bib104","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3314\/jjmm.39.11","article-title":"Topical treatment of onychomycosis by occlusive dressing using bifonazole cream containing 40% urea","volume":"39","author":"Tsuboi","year":"1998","journal-title":"Nipp Ishinkin Gakkai Zasshi"},{"key":"10.1016\/j.riam.2010.01.007_bib105","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaad.2005.06.019","article-title":"Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: Results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%","volume":"53","author":"Warshaw","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.riam.2010.01.007_bib106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1022426309340","article-title":"Inappropriate use of oral terbinafine in family practice","volume":"25","author":"Wilcock","year":"2003","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.riam.2010.01.007_bib107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1439-0507.1998.tb00344.x","article-title":"In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin","volume":"41","author":"Wildfeuer","year":"1998","journal-title":"Mycoses"},{"key":"10.1016\/j.riam.2010.01.007_bib108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1007178924408","article-title":"Use of caryophyllene oxide as an antifungal agent in an in vitro experimental model of onychomycosis","volume":"148","author":"Yang","year":"1999","journal-title":"Mycopathol"},{"key":"10.1016\/j.riam.2010.01.007_bib109","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-2008-1063858","article-title":"Update on azole antifungals","volume":"29","author":"Zonios","year":"2008","journal-title":"Semin Respir Crit Care Med"}],"container-title":["Revista Iberoamericana de Micolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113014061000015X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S113014061000015X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T09:31:07Z","timestamp":1711359067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S113014061000015X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S113014061000015X"],"URL":"https:\/\/doi.org\/10.1016\/j.riam.2010.01.007","relation":{},"ISSN":["1130-1406"],"issn-type":[{"value":"1130-1406","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}